PNC-27

Designed by Sarafraz-Yazdi, Pincus, and colleagues at SUNY Downstate Medical Center (Brooklyn, NY) circa 2000 using supercomputer-assisted epitope mapping of the p53–MDM2 interaction interface. The molecular strategy — fusing a p53-derived HDM-2-binding domain to a cell-penetrating sequence — was first described in publications from the Pincus lab. The foundational mechanism paper (Sarafraz-Yazdi et al., PNAS 2010, PMID 20080680) established selective cancer cell lysis via membrane-bound HDM-2. A 2022 Biomedicines study (PMC9138867) visualised the transmembrane pores by immuno-scanning electron microscopy. A 2024 Annals of Clinical Laboratory Science study (PMID 38802154) extended the mechanism to mitochondrial membrane disruption.

Two-step, p53-independent membranolytic mechanism. Step 1 (temperature-independent): PNC-27 binds to the p53-binding site on HDM-2 (residues 1–109) that is aberrantly expressed on the outer plasma membrane of cancer cells; cancer membranes carry 4–9-fold more surface HDM-2 than untransformed cells. Step 2 (temperature-dependent, 37°C): PNC-27–HDM-2 complexes aggregate laterally and form transmembrane pores with an average inner diameter of 34.5 ± 5.6 nm (range 28–44 nm), breaching membrane integrity and causing rapid necrotic lysis — not apoptosis; no caspase activation detected. A secondary intracellular pathway: after pore-mediated entry the peptide localises to mitochondrial membranes (confirmed by immunoelectron microscopy in PMID 38802154), causing mitochondrial disruption with loss of mitotracker retention while lysosomes remain intact. The mechanism is entirely independent of intracellular p53 status, caspase signalling, or other classic apoptosis pathways, and requires only membrane-localised HDM-2.

Sarafraz-Yazdi et al. (PNAS, 2010, PMID 20080680): PNC-27 at 50–300 μg/mL induced 100% cell death in MIA-PaCa-2 (pancreatic) and MCF-7 (breast) cancer cells within 90 min; zero cytotoxicity to untransformed MCF-10-2A, BMRPA1, and AG13145 fibroblasts; LDH release >2× background in HDM-2-transfected normal cells confirmed HDM-2 dependency. Sarafraz-Yazdi et al. (Biomedicines, 2022, PMC9138867): visualised 1:1 PNC-27–HDM-2 complexes forming pores of 28–44 nm by cryo-EM; 100% tumour-cell killing above 100 μg/mL at 37°C within minutes; effective across pancreatic, melanoma, leukemia, and ovarian lines; no effect on normal fibroblasts or pancreatic epithelial cells. Krzesaj et al. (Annals of Clinical Laboratory Science, 2024, PMID 38802154): in MIA-PaCa-2 cells gold-labelled PNC-27 particles localised to mitochondrial membranes by immunoelectron microscopy; mitotracker dye lost post-treatment (mitochondrial disruption); lysosomes unaffected. Sookraj et al. (Cancer Chemotherapy and Pharmacology, 2010, PMID 20182728): dual-fluorescent-labelled PNC-27 shown to act as intact peptide (not fragments) — yellow punctate fluorescence confirmed co-localisation at cancer membrane; normal cells showed no retained peptide and remained viable. Alagkiozidis et al. (Annals of Clinical and Laboratory Science, 2017, PMID 28667027): ovarian cancer ID8 model — PNC-27 produced dose-dependent killing; paclitaxel survivors showed elevated HDM-2 expression and heightened PNC-27 sensitivity; isobologram confirmed synergy (CI<1); combined treatment significantly reduced tumour growth in vivo. Miller et al. (Medical Research Archives, 2025): cervical cancer lines HTB-35, SW756, HeLa — IC50 7–17 μM; ketone body LiAcAc (10–15 mM) reduced IC50 by 2–3-fold; normal cervical cells unaffected at 500 μg/mL.